- Home
- NAGE vs EIC Comparison
NAGE vs EIC Comparison
Compare NAGE & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | EIC |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.2M | 228.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | EIC |
|---|---|---|
| Price | $3.49 | $9.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.00 | $12.63 |
| AVG Volume (30 Days) | ★ 719.7K | 98.5K |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $21.29 | ★ $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $9.17 |
| 52 Week High | $11.29 | $13.92 |
Technical Indicators
Market Signals| Indicator | NAGE | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 42.32 |
| Support Level | $3.35 | $9.83 |
| Resistance Level | $3.60 | $10.15 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 47.56 | 23.73 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.